Analysis of PSA, biopsy uptake predictive value and associated death in a prostate cancer screening programme
Principal Investigator
Name
Mathieu Boniol
Institution
International Prevention Research Institute
Position Title
Research Director
Email
About this CDAS Project
Study
PLCO
(Learn more about this study)
Project ID
PLCO-8
Initial CDAS Request Approval
Dec 11, 2012
Title
Analysis of PSA, biopsy uptake predictive value and associated death in a prostate cancer screening programme
Summary
PLCO and ERSPC studies provided conflicting results. Several differences exists between the two trials but there is still no clear explanation why one study showed negative result and the other showed a 20% reduction of prostate cancer mortality.
Several countries, like France, are already in a situation of quasi-screening with up to 70% of men ongoing PSA testing at the age of 60 years old.
To better understand descrepancies between studies and the situation in France, we are investigating the PSA and biopsy uptake in the PLCO and in French data from the national insurance service (which covers around 70% of men).
This analysis will also be compared to the data from autopsy series, several data from autopsy series have been gathered from systematic literature search. These autopsy series provide information on the "reservoir" of prostate cancer that could be potentially diagnosed in a screening campaign. This project will allow a better understanding on prostate cancer screening.
Finally, few information are available on the risk of death following prostate biopsy, we would like to investigate the mortality for major causes of death at 30 days, 60 days and 120 days after the biopsy.
Several countries, like France, are already in a situation of quasi-screening with up to 70% of men ongoing PSA testing at the age of 60 years old.
To better understand descrepancies between studies and the situation in France, we are investigating the PSA and biopsy uptake in the PLCO and in French data from the national insurance service (which covers around 70% of men).
This analysis will also be compared to the data from autopsy series, several data from autopsy series have been gathered from systematic literature search. These autopsy series provide information on the "reservoir" of prostate cancer that could be potentially diagnosed in a screening campaign. This project will allow a better understanding on prostate cancer screening.
Finally, few information are available on the risk of death following prostate biopsy, we would like to investigate the mortality for major causes of death at 30 days, 60 days and 120 days after the biopsy.
Aims
We would like to compare the French annual uptake of PSA tests and biopsies to reference studies like PLCO in order to better evaluate the usual care provided by the French health system. The PSA and biopsy uptake will be computed and expressed as annual rate: PSA and biopsy rate per 100 men per year. We will compute them by 5 years age group.
The predictive positive value of biopsy will be computed by age group. If PSA values of the test are available, the predictive positive value will be expressed by categories of PSA.
Mortality following biopsy, expressed as rate of deaths at 30,60,120 days, for major causes of death will be computed by age groups.
Collaborators
Pr Paul Perrin, CHU Lyon sud, Lyon
Related Publications
-
Variation of Prostate-specific Antigen Value in Men and Risk of High-grade Prostate Cancer: Analysis of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Study.
Boniol M, Autier P, Perrin P, Boyle P
Urology. 2015 May; Volume 85 (Issue 5): Pages 1117-22 PUBMED